High-dose Busulfan and Cyclophosphamide as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Childhood Non-Hodgkin Lymphoma Patients

• DOI: 10.1097/mph.0b013e3181fd6c79
• Publication Date: 2011-02-23T08:07:31Z
• Authors: Maitane Andion; Blanca Molina; Marta Gonzalez-Vi...; Laura Alonso; Carmen Hernandez; Alvaro Lassaletta; Blanca Lopez-Ibor; Marta Villa; Miguel Angel Diaz
• Keywords: Male; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Adolescent; Lymphoma, Non-Hodgkin; Transplantation, Autologous; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Recurrence; Child, Preschool; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Humans; Female; Child; Busulfan; Cyclophosphamide; Follow-Up Studies

We analyzed the outcome in 22 children with refractory or relapsed non-Hodgkin lymphoma who underwent autologous peripheral blood progenitor cell transplantation between 1994 and 2009. The conditioning regimen used in all patients consisted of busulfan and cyclophosphamide. Median age was 6 years (range 2 to 16 y). The most common histologic subtype was Burkitt lymphoma. Ten patients were in complete remission and 12 in partial remission at the time of transplant. The median dose of CD34+ cells that was infused was 4.6 × 10/kg (range 2.1 to 58.7 × 10/kg). All the patients were engrafted, with a median time for neutrophils and platelets recovery of 11 (range, 8 to 15 d) and 14 (range, 9 to 60 d) days, respectively. Nonhematologic treatment-related toxicity included severe mucositis in 3 patients and hepatic sinusoidal obstruction syndrome in 1 patient. There were no transplant-related mortalities. With a median follow-up of 60 months (range, 4 to 180 d) the disease-free survival was 90 ± 6.5% for the whole group. This retrospective study shows a high long-term survival using busulfan/cyclophosphamide as conditioning regimen in children with refractory or relapsed non-Hodgkin lymphoma.